Investor's Business Daily on MSN
Novartis Yo-Yoes As Generics Take A Bite Out Of Its First-Quarter Sales
Novartis stock was flat Tuesday after the pharma giant lagged first-quarter expectations, but retained its outlook for 2026 sales and profit.
Unless otherwise noted, all growth rates in this Release refer to same period in prior year. 2. Please see detailed guidance ...
Pharmaceutical Technology on MSN
Novartis’ Q1 sales miss hints at industry’s utilisation of M&A remedies
Novartis’ Q1 was hit by generics erosion, though its Avidity-bolstered pipeline is set for a robust future.
Executives insist Novartis will return to growth in the second half, but for Q1 2026, generic erosion drove a 5% drop in revenue, including a 46% nosedive for blockbuster heart failure drug Entresto.
Novartis AG (SIX: NOVN) reported weaker-than-expected first-quarter 2026 earnings, reflecting mounting pressure from generic ...
Novartis (SWX:NOVN) is expanding its late stage pipeline through acquisitions, highlighted by the recent purchase of Avidity Biosciences. The Avidity deal brings three late stage genetic disorder ...
SWISS drugmaker Novartis reported first-quarter core operating profit and sales below market expectations on Tuesday, as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results